Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

titute
  • Location: Ernest N. Morial Convention Center, Hall E.
  • Additional Abstracts

    In addition to the abstract accepted for presentation, two additional abstracts describing  EphA3 expression and screening in myeloid malignancies were accepted for publication online and in the ASH conference materials. These abstracts outline An Immunohistochemistry (IHC) Screen For EphA3 Positive Tumors and Analysis of EphA3 Expression in Hematologic Malignancies by Quantitative PCR.

    "These published abstracts further detail our ongoing research efforts on EphA3," stated Dr. Geoffrey Yarranton, Chief Scientific Officer and Executive Vice President of Research and Development at KaloBios. "We continue to work to understand EphA3 expression on various tumor types, and we now have a validated EphA3 screening test operative at a CLIA laboratory to screen patients' tumor biopsies before entry into the Phase 2 portion of Study KB004-01 in AML and MDS."

    About KaloBios

    KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer.

    Currently, KaloBios has three drug development programs:

    • KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, being developed for the treatment of severe asthma. Enrollment of 160 patients has been completed in a Phase 2 study in the United States, Europe and Australia.
    • KB001-A, an anti-PcrV mAb fragment that is partnered exclusively with Sanofi Pasteur and is being developed for the prevention and treatment of Pa infections. KaloBios has retained right
      '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology news :

    1. Cell therapy using patients own bone marrow may present option for heart disease
    2. Report presents designs for study of cancer risks near US nuclear facilities
    3. Entomology 2012 to present 105 insect symposia in November
    4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
    5. The Brain Prize 2012 is presented May 9th
    6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
    7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
    8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
    9. Coral reef experts to present latest coral reef science during July symposium
    10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
    11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/10/2014)... on U.S. store shelves in early 2010, and people ... small packets can be tossed into a washing machine ... powder. The convenience, though, has come with risks for ... Nationwide Children,s Hospital found that from 2012 through 2013, ... younger than 6 years of age swallowing, inhaling, or ...
    (Date:11/6/2014)... groundbreaking paper from a team of Florida State University ... plants could adapt to and survive environmental swings such ... the latest issue of the journal The Plant ... of DNA and proteins) is organized in a cell ... genes are turned on and others are turned off. ...
    (Date:11/5/2014)... of biology in the UTSA College of Sciences, ... selected to receive a two-year $300,00 National Science ... (EAGER). The funding supports President Obama,s BRAIN Initiative, ... new technology that will demystify complex brain processes. ... neuroscience are broken into the interactions of multiple ...
    Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
    ... WORCESTER, MA Scientists at the University of Massachusetts ... piecing together the short DNA reads produced by next-generation ... genome sequences. Job Dekker, PhD, and colleagues have shown ... accurately by measuring the frequency of interactions between DNA ...
    ... great number of women experience depression or anxiety while ... mood disorders may lead to long-term emotional and behavioral ... the fetal environment has a strong influence on offspring ... exact mechanisms by which this occurs are not completely ...
    ... 2013, Cleveland: Cleveland Clinic researchers Richard A. Padgett, Ph.D., and ... American Association for the Advancement of Science (AAAS). This year,s ... & Notes section of the journal Science on ... Department of Molecular Genetics at the Lerner Research Institute, was ...
    Cached Biology News:University Of Massachusetts Medical School scientists re-imagine how genomes are assembled 2University Of Massachusetts Medical School scientists re-imagine how genomes are assembled 32 Cleveland Clinic researchers honored for contribution to science 2
    (Date:11/26/2014)... NC (PRWEB) November 25, 2014 ... Intensity Focused Ultrasound (HIFU) devices, recently participated in ... Small Renal Mass 360° .” Key opinion leaders ... therapeutic advances related to small renal masses while ... about different ablative technologies in hands-on labs. Attendees ...
    (Date:11/26/2014)... Miles Holder, formerly of Micron Research and ... team as Sales/Marketing Manager. Mr. Holder has over 25 ... the graphite industry. , “We are thrilled to be ... Trinkley, VP of Market and Product Development for Graphel ... the graphite industry, along with his proven track record ...
    (Date:11/26/2014)... 2014 Bio-Techne Corporation (NASDAQ: TECH ... Gavin to serve in a newly created position ... Mr. Gavin will be responsible for managing the operations ... ProteinSimple business acquired in July 2014 and the recently ... California -based ProteinSimple develops and commercializes proprietary systems ...
    (Date:11/24/2014)... , Nov. 24, 2014  Last week, Representatives ... Butterfield (D-NC) took a bold bipartisan step ... introducing the OPEN Act. Original co-sponsors of the ... The Act will incentivize drug makers and innovators ... diseases and pediatric cancers, which opens the door ...
    Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
    ... SAN DIEGO, Sept. 27, 2011 Verenium Corporation (Nasdaq: ... developing and commercializing high-performance enzymes, today announced that it ... an aggregate of $34.9 million in principal amount of ... repurchase of approximately $1.1 million in principal amount of ...
    ... Circassia Ltd, a specialty biopharmaceutical company focused ... results showing that its ToleroMune® hay fever vaccine ... on placebo.  The treatment was extremely well tolerated. ... phase II study conducted in 50 hay fever ...
    ... Chemical Engineering department and the Kavli institute of Delft ... electrons can move freely in layers of linked semiconductor ... will be very useful for the development of cheap ... their findings on Sunday 25 September on the website ...
    Cached Biology Technology:Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial 2Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial 3TU Delft: cheap and efficient solar cell made possible by linked nanoparticles 2
    ... screening and binding optimization and built on ... synthesis platform. These microarrays are available as ... Service. Probe Content Our ... than 1500 known aptamer sequences. Add up ...
    ... Sciences provides a comprehensive epitope analysis ... synthesized on Paraflo microfluidic chips for ... development. This comprehensive service includes assistance ... using sample(s) provided by you, single ...
    ... is an extension of Parkers MX80 family of ... cross-section. LX80L bolt hole patterns mimic the MX80 ... and all accessory brackets to build multi-axis systems., ... to 750 mm , Accelerations to 5 gs ...
    ... LabLinx is the next step in ... modular, expandable track system that delivers labware ... up to 10 times the throughput of ... to setup a variety of configurations to ...
    Biology Products: